First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours

Objective W0180 is a humanised IgG1κ antagonistic monoclonal antibody against the V domain-containing immunoglobulin suppressor of T-cell activation (VISTA) designed to enhance antitumour activities by inhibiting the immunosuppressive role of VISTA in myeloid cells and T cells in solid tumours.Metho...

Повний опис

Бібліографічні деталі

Автори:	Stephane Champiat, Francois-Xavier Danlos, Aurélien Marabelle, Ignacio Melero, Carlos Gomez-Roca, Aurelie Petain, Claire Fabre, Eduardo Castañón Álvarez, Philippe Alexandre Cassier, Elena Dupuy, David Jegou, Marie Primard, Mathilde Saccareau, Geneviève Gueguen-Dorbes
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMJ Publishing Group 2026-02-01
Серія:	BMJ Oncology
Онлайн доступ:	https://bmjoncology.bmj.com/content/5/1/e000854.full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!